Takeda Pharmaceutical Co Ltd
TKD
Company Profile
Business description
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Contact
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku
Tokyo103-8668
JPNT: +81 332782306
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
49,281
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,496.00 | 31.00 | 0.37% |
| CAC 40 | 7,393.76 | 13.02 | 0.18% |
| DAX 40 | 20,024.66 | 115.52 | 0.58% |
| Dow JONES (US) | 42,392.27 | 151.95 | -0.36% |
| FTSE 100 | 8,260.09 | 87.07 | 1.07% |
| HKSE | 19,644.21 | 20.89 | 0.11% |
| NASDAQ | 19,280.79 | 30.00 | -0.16% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,018.44 | 92.30 | -0.70% |
| S&P 500 | 5,868.55 | 13.08 | -0.22% |
| S&P/ASX 200 | 8,233.80 | 32.60 | 0.40% |
| SSE Composite Index | 3,250.81 | 11.75 | -0.36% |